[A further contribution to the knowledge of the Hallervorden-Spatz disease].
D000293:Adolescent; D001927:Brain Diseases / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D003676:Deferoxamine / Q000008:administration & dosage; D005917:Globus Pallidus / Q000473:pathology; D006801:Humans; D007501:Iron / Q000378:metabolism; D007503:Iron Isotopes; D008297:Male; D008970:Molecular Weight; D009069:Movement Disorders; D006211:Pantothenate Kinase-Associated Neurodegeneration / Q000175:diagnosis; D013378:Substantia Nigra / Q000473:pathology
D007503:Iron Isotopes; D007501:Iron; D003676:Deferoxamine
Acta Neuropathol. 1965 Oct 4;5(1):1-15
5886195
Acta Neuropathol. 1968 Jan 2;10(1):1-16
5640114
J Neuropathol Exp Neurol. 1964 Oct;23:567-83
14219098
J Neuropathol Exp Neurol. 1964 Jan;23:60-77
14105310
Acta Neuropathol. 1963 Sep 2;3:16-28
14197653
Arch Neurol. 1966 Apr;14(4):438-42
5948398
Arch Psychiatr Nervenkr. 1964 Mar 16;205:178-91
14172823
Weiterer Beitrag zur Kenntnis der Hallervorden-Spatzschen Krankheit.